What is the health risk from Ebola and how is it contained?

Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.

1. 1

   Ebola (Wikipedia)

   WikipediaPublished Oct 12, 2026Checked Oct 14, 2026

   “Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a zoonotic viral hemorrhagic fever in humans and other primates, caused by four of the six known ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash, hepatic and renal dysfunction, at which point some people begin to bleed both internally and externally. Outbreaks of the disease have had a mortality rate of between 25 and 90%, averaging out at approximately 50%. The viral species involved and timing of treatment play a critical role in its prognosis. Death is often due to shock from fluid loss, and typically occurs between 6 and 16 days after the first symptoms appear. The viruses have caused intermittent outbreaks in sub-Saharan Africa since 1976 when the disease was first reported, with the largest one being the 2013–16 Western African epidemic.”

2. 2

   Clinical factors associated with mortality in ebola virus disease: a systematic review and meta-analysis.

   BMC infectious diseases (Kayembe et al.)Published May 20, 2026Checked Oct 14, 2026

   “Publication bias was evaluated using funnel plots and Egger's and Begg's tests.ResultsEleven studies involving 16,413 patients with EVD were included. Reported case fatality proportions ranged from 34% to 79%. The pooled mortality was 54% (95% CI: 45-63), with very high heterogeneity (I² = 98.2%). Mortality was higher during the West African epidemic (2014-2016) than during more recent Central African outbreaks (2018-2020). Pediatric mortality appeared lower than adult mortality, although confidence intervals overlapped. Hemorrhagic manifestations were strongly associated with death, whereas age was not independently associated with mortality in pooled analyses. No significant publication bias was detected.ConclusionsEVD remains associated with high mortality, although improvements in outcomes are evident in more recent outbreaks. Hemorrhagic manifestations represent a key clinical determinant of death. These findings highlight the importance of early access to care, high-quality supportive management, and sustained implementation of effective therapeutic strategies to further reduce EVD-related mortality, particularly in resource-limited settings.”

3. 3

   Mapping the global evidence base of bundibugyo ebolavirus disease: a systematic scoping review of research gaps and preparedness priorities.

   BMC infectious diseases (Boatemaa et al.)Published Jul 9, 2026Checked Oct 14, 2026

   “Applying the conceptual model revealed pronounced asymmetries across the research domains: the literature remains heavily concentrated within upstream epidemiological drivers and clinical features. Conversely, critical health system response domains lack validated tools; no licensed vaccine, specific therapeutic agent, or point-of-care rapid diagnostic test validated for BDBV currently exists. While cross-reactive monoclonal antibodies show preclinical efficacy, clinical-grade validation remains absent, and longitudinal survivor outcomes are sparsely documented. Systemic moderators, particularly weak health infrastructure and conflict, continue to compound these gaps. Methodological risk of bias was moderate, driven by missing outcome data (42% of studies) and selective reporting (41%).ConclusionsBDBV remains understudied relative to its epidemic potential. Sustained, internationally coordinated investments modeled on prior EBOV frameworks are required to transition from reactive to proactive research models.Clinical trial numberNot applicable.”

4. 4

   Bundibugyo virus disease evidence map: a rapid research needs appraisal.

   EClinicalMedicine (Sigfrid et al.)Published Sep 3, 2026Checked Oct 14, 2026

   “Fever, vomiting, diarrhoea, headache, fatigue, dysphagia, anorexia, dyspnoea and abdominal pain were the most commonly reported symptoms. Haemorrhagic manifestations ranged from 10.4 to 54.0%, with a meta-analysis estimating a CFR of 32.8% (CI 25.8-40.2) based on past outbreaks. Evidence on cross-reactivity to previous Ebola exposure following natural infection of vaccination was sparse and conflicting. One study identified low levels of cross-reactivity in EBOV vaccinated participants, another among EBOV survivors, whereas a third did not detect cross-reactivity following EBOV vaccination. Long-term sequelae, persistent BVD survivor stigma and limited community awareness were also reported.InterpretationWhilst acknowledging the limitations of such a rapid appraisal, our findings show that urgent, coordinated investment is needed in countermeasure trials inclusive of pregnant women and children, supported by observational studies community engagement and co-production.FundingThe National Institute for Health Research (NIHR) and the Wellcome Trust.”

5. 5

   The Re-Emergence of Bundibugyo Ebolavirus in Uganda and the Democratic Republic of Congo: Epidemiological Drivers, Response Strategies, and Implications for Global Health Security.

   Infection and drug resistance (Olwit et al.)Published Sep 3, 2026Checked Oct 14, 2026

   “rizes peer-reviewed literature, preprints, and official situation reports from WHO, Africa CDC, US CDC, ECDC, and national health ministries, identified through PubMed, Scopus, Web of Science, Google Scholar, and Embase from inception to 12 August 2026, to examine BDBV historical evolution, virology and pathogenesis, drivers of re-emergence, surveillance and response, therapeutic and vaccine gaps, and global health security implications. The 2026 outbreak, unfolding amid conflict and mass displacement in eastern DRC, has been marked by an estimated basic reproduction number of 1.4-2.1 (central estimate 1.71), disproportionate infection among healthcare workers (7.2% of confirmed cases in DRC, 20% in Uganda), and the continued absence of licensed BDBV-specific vaccines or therapeutics. Findings underscore the need for sustained genomic and ecological surveillance, decentralized rapid diagnostics, broadly protective pan-filovirus vaccines, conflict-sensitive response strategies, and strengthened Uganda-DRC collaboration. Because the evidence base for the ongoing outbreak remains preliminary, findings should be interpreted cautiously and revisited as further peer-reviewed data emerge.”